Advertisement
Singapore markets close in 58 minutes

  • Straits Times Index

    3,277.78
    -9.97 (-0.30%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,661.10
    +376.56 (+2.18%)
     

  • FTSE 100

    8,123.44
    +44.58 (+0.55%)
     

  • Bitcoin USD

    64,294.30
    +296.32 (+0.46%)
     

  • CMC Crypto 200

    1,388.37
    -8.17 (-0.58%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,358.00
    +15.50 (+0.66%)
     

  • Crude Oil

    84.00
    +0.43 (+0.51%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,574.42
    +5.17 (+0.33%)
     

  • Jakarta Composite Index

    7,072.56
    -82.73 (-1.16%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Barclays Sticks to Their Hold Rating for Halozyme Therapeutics

Investing.com
·1-min read


Barclays (LON:BARC) analyst Gena Wang maintained a Hold rating on Halozyme (NASDAQ:HALO) Therapeutics on Tuesday, setting a price target of $21, which is approximately 15.39% below the present share price of $24.82.

Wang expects Halozyme Therapeutics to post earnings per share (EPS) of -$0.24 for the second quarter of 2020.

The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Halozyme, with an average price target of $26.86.
The analysts price targets range from a high of $39 to a low of $13.

In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $53.67 million and a net profit of -$32.06 million. The company's market cap is $3.27 billion.

ADVERTISEMENT

According to TipRanks.com, Barclays analyst Gena Wang is a 5-star analyst with an average return of 20.1% and a 55.2% success rate.

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.